DOCKET NO.: RTS-0242US.P1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: C. Frank Bennett

Serial No.:

10/672,866

Group Art Unit: 1635

Filed:

September 26, 2003

Examiner: Kimberly Chong

For:

Antisense Modulation of Superoxide Dismutase 1, Soluble

aura Eames hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or being facsimile transmitted to the USPTO, on the date indicated helow.

Commissioner for Patents Mail Stop: Fee Amendment

PO Box 1450

Alexandria, VA 22313-1450

AMENDMENT AND REQUEST FOR RECONSIDERATION

Dear Examiner Chong:

This is in response to the Office Action dated May 3, 2005 setting a three (3) month period for response. The Applicants hereby request an extension of one (1) month in time for response.

Applicants respectfully request that the following amendments be entered, without prejudice:

Amendments to the Specification begin on page 2.

Amendments to the Claims begin on page 3.

Amendments to the Sequence Listing begin on page 5.

Remarks begin on page 6.

DOCKET NO.: RTS-0242US.P1

PATENT

→ PATENT OFFICE

This version of the paragraph on page 127, line 29 to page 128, line 13 will replace all prior versions of the paragraph in the specification:

In accordance with the present invention, a series of nucleic acid duplexes comprising the antisense compounds of the present invention and their complements can be designed to target superoxide dismutase-1, soluble. The nucleobase sequence of the antisense strand of the duplex comprises at least a portion of an oligonucleotide to superoxide dismutase-1, soluble as described herein. The ends of the strands may be modified by the addition of one or more natural or modified nucleobases to form an overhang. The sense strand of the dsRNA is then designed and synthesized as the complement of the antisense strand and may also contain modifications or additions to either terminus. For example, in one embodiment, both strands of the dsRNA duplex would be complementary over the central nucleobases, each having overhangs at one or both termini. For example, a duplex comprising an antisense strand having the sequence CGAGAGGCGGACGGGACCG and having a two-nucleobase overhang of deoxythymidine(dT) would have the following structure:

cgagaggcggacgggaccgTT
||||||||||||||
TTgctctccgcctgccctgqc

Antisense Strand (SEQ ID NO: 340)

Complement (SEQ ID NO: 341)

RECEIVED CENTRAL FAX CENTER

ISIS PATENT DEPT

AUG 2 9 2005

TRANSMITTAL FORM	Persons are required to respond to a color Application Number Filing Date First Named Inventor Art Unit Examiner Name	PTOSSEZION Approved for use through 07/31/2006. CMB 05 Patent and Trademark Office; U.S. DEPARTMENT OF COMModelection of information unlass it displays a valid OMB control of 10/672,866 9/26/2003 C. Frank Bennett 1635 Kimberly Chong RTS-0242US.P1	1-0031 MERCE
Total Number of Pages in This Submission			
Fee Transmittal Form Fee Attached Amendment/Repty After Final Affildavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement	ENCLOSURES (Check all Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocatio Change of Correspondence A Terminal Discialmer Request for Refund CD, Number of CD(s) Landscape Table on CI	Address Status Letter Other Enclosure(s) (please identification):	-
Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	RECEIVED OIPE/IAP AUG 3 0 2005	·
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Isis Pharmaceuticals, Inc. Signature Printed name Colleen J. McKieman, Ph.D. Date Lug 29, 200 S		Reg. No. 48/570	
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature			
Stule 8	m—	Date docume	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Contidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chtef Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.